HABERMAN ASSOCIATES NEWS PAGE ARCHIVE
 
2006 News
December 20, 2006: Allan B. Haberman, Ph.D. was interviewed for and quoted in an article entitled "Staying the Course" by Beth Herskovits, in the December 20 issue of Pharmaceutical Executive's weekly newsletter PharmExec Direct.  The article was about pipeline drugs to raise HDL, or "good cholesterol". These included Merck's MK-0859 and Roche's JTT705, which are Phase II cholesterol ester transfer protein (CETP) inhibitors, the same class as Pfizer's discontinued compound torceptrapib. The article also highlighted other pipeline HDL-raising drugs, which work via different mechanism of action.

The article is available at http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=393506
 

December 1, 2006: Allan B. Haberman, Ph.D. was interviewed for and quoted in Pharmaceutical Executive's 2006 Pipeline Report. The Pipeline Reports are an annual feature, published in the December issue of Pharmaceutical Executive, which review promising drugs in development. The 2006 report focuses on pipeline drugs for type 2 diabetes, Alzheimer's disease, oncology, hepatitis C, obesity, dyslipidemia, and respiratory diseases.

Dr. Haberman was quoted in conjunction with reviews of GlaxoSmithKline's Tykerb (lapatinib), in Phase III clinical trials for breast cancer, and AstraZeneca's Zactima (vandetanib), in Phase III clinical trials for lung and thyroid cancer. In a sidebar to the Pipeline Report entitled "6 Oncology Drugs to Watch", Dr. Haberman was also quoted with respect to issues in pricing of oncology drugs.

The article is available at http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=389274

November 1, 2006: Allan B. Haberman, Ph.D. served on the faculty of a course entitled “Cardiovascular Drug Development”, offered by the Pharmaceutical Education and Research Institute (PERI) on November 1-3 2006 at the PERI Training Facility in Arlington, VA. Dr. Haberman’s presentation was entitled “New Therapeutic Approaches to Cardiovascular Disease Management”. PERI is a not-for-profit organization that provides training and continuing education for pharmaceutical industry professionals. This is the second year in a row in which PERI offered this course with Dr. Haberman's participation.
 

October 19, 2006: Pharma DD published an article by Allan B. Haberman, Ph.D. in its October 19, 2006 web edition, entitled "Recent Clinical Developments in Type 2 Diabetes: Preventing Diabetes and Preventing Cardiovascular Events in Diabetics".

For more information on Pharma DD, see the entry for September 22, 2006.
 

September 22, 2006: Pharma DD published an article by Allan B. Haberman, Ph.D. in its September 22, 2006 web edition, entitled "Safety Issues Hamper Dual PPAR Agonists: Is Partial Antagonism the Solution?"

Pharma DD is a new periodical published by Cambridge Healthtech Institute. The publication and accompanying web site www.pharmadd.com provides senior researchers and scientific management with unique insight into the industry-leading techniques and approaches driving new therapeutic discovery and development. They also focus on business issues, regulatory considerations, clinical trials, and post-approval safety issues.
 

June 23, 2006: Cambridge Healthtech Advisors (CHA) announced the publication of a new book-length report, Emerging Targets in Diseases with High Unmet Need: Alzheimer’s Disease, Lung Cancer, Dyslipidemia, Type 2 Diabetes, and COPD, by Allan B. Haberman, Ph.D.

This report is a survey of emerging targets in these important diseases. It assesses the issues in target-based drug discovery and development as well as several specific issues that are common to these and other complex diseases with high unmet medical need.

Comprehensive analysis includes the following:

• Background discussion of the nature of each disease.
• Mechanistic characterization of each disease, and major issues in diagnosis, stratification, and treatment of each disease.
• Evaluation of leading emerging targets in terms of signaling pathways and therapeutic strategies.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.